1988
DOI: 10.1007/bf00176844
|View full text |Cite
|
Sign up to set email alerts
|

Unaltered 5-HT- and desipramine-sensitive [3H]imipramine binding and [3H]5-HT uptake in rat brain after chronic imipramine and norzimeldine treatment

Abstract: Several reports have shown heterogeneity of [3H]imipramine binding to brain membranes. Recently, a high affinity and 5-HT sensitive [3H]imipramine binding site of protein nature, that was suggested to be identical to the substrate recognition site for 5-HT uptake, was demonstrated. Since most studies on the regulation of the [3H]imipramine binding sites by antidepressants have used desipramine displaceable binding, which is heterogenous in nature and contains binding not related to 5-HT uptake sites, the prese… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1990
1990
1992
1992

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 10 publications
(1 citation statement)
references
References 12 publications
0
1
0
Order By: Relevance
“…vary with regard to the uptake inhibitor and dose utilized as well as the duration of treatment and the withdrawal interval. However, chronic treatment with selective 5-HT uptake inhibitors (e.g., chlorimipramine, fluoxetine, fluvoxamine) generally decreased (Brunello et al, 1987;Hrdina, 1987;Montero et al, 1990) or had no effect (Marcusson et al, 1988) on L3Hlimipramine binding to crude synaptic preparations from rat brain. Similar repeated exposure to selective 5-HT uptake inhibitors, such as citalopram, indalpine, and zimelidine, decreased the sensitivity of 5-HT DR neurons to 5-HT and 5-HTIA autoreceptor agonists (Blier and de Montigny, 1983;Blier et al, 1984;1988;Chaput et al, 1986), although alterations in response to a 5-HT uptake inhibitor as described here has not yet been assessed.…”
Section: Scheelmentioning
confidence: 98%
“…vary with regard to the uptake inhibitor and dose utilized as well as the duration of treatment and the withdrawal interval. However, chronic treatment with selective 5-HT uptake inhibitors (e.g., chlorimipramine, fluoxetine, fluvoxamine) generally decreased (Brunello et al, 1987;Hrdina, 1987;Montero et al, 1990) or had no effect (Marcusson et al, 1988) on L3Hlimipramine binding to crude synaptic preparations from rat brain. Similar repeated exposure to selective 5-HT uptake inhibitors, such as citalopram, indalpine, and zimelidine, decreased the sensitivity of 5-HT DR neurons to 5-HT and 5-HTIA autoreceptor agonists (Blier and de Montigny, 1983;Blier et al, 1984;1988;Chaput et al, 1986), although alterations in response to a 5-HT uptake inhibitor as described here has not yet been assessed.…”
Section: Scheelmentioning
confidence: 98%